Pharmaceuticals,
Journal Year:
2024,
Volume and Issue:
17(12), P. 1714 - 1714
Published: Dec. 19, 2024
Background:
Antidepressants
such
as
SSRIs
and
SNRIs
are
widely
prescribed;
however,
significant
concerns
exist
regarding
psychiatric
adverse
drug
reactions
(ADRs),
particularly
suicidal
ideation,
suicide
attempts,
completed
suicides.
This
study
analyzes
pharmacovigilance
(PhV)
data
from
the
EudraVigilance
database
to
assess
frequency
of
ADRs,
including
suicide-related
events,
associated
with
six
commonly
used
antidepressants.
Another
aim
is
evaluate
utility
in
providing
insights
into
real-world
risks
medications,
highlighting
importance
improving
ADR
reporting
system
ensuring
completeness
reliability
reports.
Methods:
Data
December
2001
September
2024
were
analyzed
for
duloxetine,
citalopram,
escitalopram,
fluoxetine,
venlafaxine,
sertraline.
Reports
categorized
by
age,
gender,
source,
focusing
on
ADRs
suicides
attempts.
Results:
Psychiatric
accounted
a
substantial
portion
total
reported
studied
antidepressants,
ranging
33.9%
38.2%.
Venlafaxine
had
highest
count
(13,134
cases),
duloxetine
showing
relative
percentage
(38.2%).
Completed
most
frequent
venlafaxine
(1635
while
was
observed
fluoxetine
citalopram
(6%).
occurred
more
frequently
women,
(67%)
sertraline
(61.3%),
attempts
prevalent
patients
aged
18–64,
notable
incidence
0–17
age
group.
Conclusions:
highlights
patterns,
risks,
underreporting
prescribed
Using
worst-case
scenario
approach,
it
reveals
extent
gender
disparities,
impact
incomplete
risk
assessment.
The Journal of Rheumatology,
Journal Year:
2025,
Volume and Issue:
unknown, P. jrheum.2024 - 1273
Published: Jan. 15, 2025
Among
adults
with
arthritis
in
the
United
States,
anxiety
and
depression
are
twice
as
common
compared
to
among
general
population1;
prevalence
even
higher
rheumatoid
(RA).
Likewise,
psoriatic
is
associated
increased
odds
of
depression,2
a
systemic
lupus
erythematosus
metaanalysis
reported
around
25%,3
RA,
was
~37%
1
study.4
Journal of Comparative Effectiveness Research,
Journal Year:
2025,
Volume and Issue:
14(2)
Published: Jan. 27, 2025
Aim:
To
compare
the
safety
and
efficacy
of
antidepressants
(AD)
among
older
adults
with
major
depressive
disorder
(MDD)
by
assessing
treatment
change,
augmentation
hospitalization
rates.
Methods:
This
retrospective
study
analyzed
data
from
Veterans
Affairs
(VA)
database,
including
142,138
patients
aged
≥60
years
diagnosed
MDD.
Patients
prescribed
bupropion,
citalopram,
duloxetine,
escitalopram,
fluoxetine,
mirtazapine,
paroxetine,
sertraline,
or
venlafaxine
were
included.
Outcomes
Hazard
ratios
(aHRs)
calculated
using
sertraline
as
reference.
Results:
Of
patients,
39.6%
required
augmentation,
18.1%
changed
antidepressant
13.3%
hospitalized.
The
corresponding
incidence
rate
was
544,
124
122
events
per
1000
person-years.
Compared
mirtazapine
users
had
highest
AD
change
risk
(aHR
1.34,
95%
CI:
1.29-1.40),
while
duloxetine
lowest
0.87,
0.83-0.92).
Duloxetine
also
0.89,
0.86-0.92).
Mirtazapine
risks
1.15,
1.12-1.18)
1.14,
1.07-1.23).
Bupropion
0.77,
0.71-0.84).
Conclusion:
Antidepressant
choice
significantly
influences
outcomes
in
demonstrated
best
profile
posed
all
three
outcomes.
Personalized
strategies
are
crucial
to
improving
this
population.
Frontiers in Medicine,
Journal Year:
2025,
Volume and Issue:
12
Published: March 12, 2025
Background
Functional
dyspepsia
(FD)
is
a
prevalent
health
issue
currently
lacking
optimal
treatment
options,
with
its
global
incidence
rate
increasing
in
recent
years.
Clinical
studies
have
recently
focused
on
the
application
of
auriculotherapy
functional
gastrointestinal
disorders
that
are
accompanied
by
negative
emotions.
However,
few
randomized
controlled
trials
investigated
use
for
FD
patients
insomnia,
leaving
therapeutic
efficacy
and
safety
largely
undefined.
This
study
aims
to
evaluate
clinical
treating
insomnia.
Methods
analysis
single-center,
trial
involving
80
Using
central
randomization
system,
subjects
randomly
assigned
auricular
acupressure
group
or
sham
at
1:1
ratio,
targeting
concha
region
earlobe
region.
The
primary
outcome
response
2
weeks,
secondary
outcomes
include
8
sleep
data
assessed
actigraphy,
modified
Dyspepsia
Symptom
Diary,
short
form-Nepean
Index,
Self-rated
Anxiety
Scale,
Depression
High
Arousal
Heart
Rate
Variability.
Efficacy
results
will
be
evaluated
baseline
weeks
after
treatment.
Adverse
events
monitored
throughout
observation
period.
Discussion
this
anticipated
validate
improving
symptoms
as
well
reducing
emotional
states.
registration
ClinicalTrials.gov
,
NCT06466044.
Registered
14th
May
2024,
https://register.clinicaltrials.gov
.
Respiratory Care,
Journal Year:
2024,
Volume and Issue:
69(6), P. 664 - 677
Published: April 30, 2024
Pulmonary
rehabilitation
(PR)
improves
exercise
capacity
and
quality
of
life
(QOL)
while
reducing
dyspnea
in
patients
with
COPD.
However,
little
is
known
about
the
efficacy
PR,
cognitive
behavioral
therapy
(CBT),
or
antidepressant
drug
on
psychosocial
factors
Knowledge
gaps
include
which
most
efficacious,
what
barriers
exist
for
each
treatment,
optimal
duration
intervention.
Potential
to
patient
fears
potential
adverse
effects,
apprehension
misconception,
stigma
related
depression.
Both
CBT
PR
reduce
anxiety
depressive
symptoms
short-term
studies.
their
benefits
over
medium-to-long-term
follow-up
specifically
warrant
exploration.
Furthermore,
new
emerging
treatment
strategies
such
as
collaborative
care
model
home-based
telehealth
coaching
are
promising
interventions
promote
patient-centered
adversely
affecting
This
update
critical
synthesis
reviews
effectiveness
both
pharmacologic
non-pharmacologic
It
also
provides
brief
screening
tools
used
assessment
depression
Journal of Affective Disorders,
Journal Year:
2024,
Volume and Issue:
367, P. 244 - 254
Published: Sept. 3, 2024
To
investigate
a
wide
range
of
sociodemographic
and
clinical
factors
associated
with
treatment
outcomes
in
older
adults
who
initiated
an
SSRI
for
depression
real-world
setting.
